Table 2.

Univariate and multivariate analyses of factors for clinical cure, microbiological success, and 28-day survival

Variable	Unadjusted OR (95% CI)	P value	Adjusted ORa (95% CI)	P value
Clinical cureb
CAZ-AVI use	2.561 (1.138–5.764)	0.023	4.767 (1.694–13.414)	0.003
Age	0.966 (0.943–0.989)	0.004	0.966 (0.935–0.997)	0.034
VAP	0.412 (0.173–0.979)	0.045	0.560 (0.200–1.564)	0.268
Renal replacement therapy	0.318 (0.131–0.773)	0.011	0.351 (0.110–1.117)	0.076
SOFA score at onset of infection	0.801 (0.694–0.924)	0.002	0.802 (0.681–0.945)	0.008
Charlson’s score	0.823 (0.687–0.985)	0.033	1.011 (0.791–1.293)	0.927
Mechanical ventilation	0.150 (0.029–0.762)	0.022
APACHE II score at onset of infection	0.915 (0.852–0.984)	0.016
Microbiological successc
CAZ-AVI use	5.680 (2.395–13.471)	< 0.001	6.664 (2.626–16.915)	< 0.001
SOFA score at onset of infection	0.963 (0.879–1.055)	0.418	0.917 (0.824–1.020)	0.112
Age	0.986 (0.964–1.007)	0.193	0.992 (0.969–1.016)	0.508
28-day survivald
CAZ-AVI use	1.182 (0.512–2.729)	0.695	1.284 (0.470–3.509)	0.626
Age	0.946 (0.917–0.975)	< 0.001	0.964 (0.926–1.003)	0.070
Heart disease	0.208 (0.077–0.565)	0.002	0.326 (0.092–1.157)	0.083
Chronic pulmonary disease	0.256 (0.057–1.142)	0.074	0.507 (0.089–2.896)	0.445
SOFA score at onset of infection	0.883 (0.797–0.979)	0.018	0.864 (0.765–0.975)	0.018
Charlson score	0.850 (0.722–1.002)	0.052	1.076 (0.867–1.335)	0.504
APACHE II score at onset of infection	0.887 (0.825–0.954)	0.001

^aCAZ-AVI use, some meaningful indicators by clinical judgment, and the other variables with P < 0.10 (in the univariate analysis) were included in the multivariate analysis (some factors have been excluded for the multivariate analysis to prevent multicollinearity)

^bDiscrimination (AUC = 0.809) and calibration (Hosmer–Lemeshow χ² = 13.519; P = 0.095)

^cDiscrimination (AUC = 0.743) and calibration (Hosmer–Lemeshow χ² = 14.239; P = 0.076)

^dDiscrimination (AUC = 0.727) and calibration (Hosmer–Lemeshow χ² = 8.439; P = 0.392)